Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone

Hydrofluoroalkane-134a (HFA) beclomethasone dipropionate (BDP) was formulated in a metered-dose inhaler (MDI) to deliver a particle size of 1.1 microm compared with 35 microns for currently marketed chlorofluorocarbon (CFC)-BDP products. Two phase I single-dose human deposition studies were conducted using technetium 99m-radiolabelled BDP in a press-and-breathe actuator without an add-on spacer. A healthy volunteer study (n=6) showed that 55-60% of the HFA-BDP ex-actuator dose was deposited in the lungs, with 29-30% deposited in the oropharynx. CFC-BDP deposition was 4-7% in the lungs and 90-94% in the oropharynx. The pattern of deposition within the lung showed that HFA-BDP was spread diffusely throughout the lung airways, whereas CFC-BDP was confined to the central airways with little, if any, peripheral airway deposition. A second study with asthmatics (n=16) confirmed that 56% of the HFA-BDP dose was deposited in the airways, with 33% in the oropharynx. In conclusion, hydrofluoroalkane-134a-beclomethasone dipropionate deposition was much greater in the airways than chlorofluorocarbon-beclomethasone dipropionate, with a concomitant reduction in oropharyngeal deposition. The increased lung deposition efficiency of the hydrofluoroalkane propellant has led to a reduction in the amount of beclomethasone dipropionate needed to achieve a similar efficacy. The penetration of the hydrofluoroalkane to the small airways may provide asthma treatment not afforded by conventional chlorofluorocarbons.

This article has been cited by other articles:

				B. Caldwell, S. Dickson, C. Burgess, R. Siebers, S. Mala, A. Parkes, and J. Crane A pilot study of nicotine delivery to smokers from a metered-dose inhaler Nicotine Tob Res, April 3, 2009; (2009) ntp027v1. [Abstract] [Full Text] [PDF]

				Switching to CFC-free beclometasone for asthma DTB, June 1, 2008; 46(6): 46 - 48. [Abstract] [Full Text] [PDF]

				K. T. Kim, H. Milgrom, Y. K. Yoon, A. L. Levy, P. Matz, M. J. Welch, A. Cahn, D. A. Collins, S. Kathman, R. Mehta, et al. Systemic Exposure and Urinary Cortisol Effects of Fluticasone Propionate Formulated With Hydrofluoroalkane in 4- to 11-Year-Olds With Asthma J. Clin. Pharmacol., January 1, 2008; 48(1): 108 - 116. [Abstract] [Full Text] [PDF]

				R. A.M. Al-Showair, S. B. Pearson, and H. Chrystyn The Potential of a 2Tone Trainer To Help Patients Use Their Metered-Dose Inhalers Chest, June 1, 2007; 131(6): 1776 - 1782. [Abstract] [Full Text] [PDF]

				A. Papi, P. L. Paggiaro, G. Nicolini, A. M. Vignola, L. M. Fabbri, and on behalf of the Inhaled Combination Asthma Treatm Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Eur. Respir. J., April 1, 2007; 29(4): 682 - 689. [Abstract] [Full Text] [PDF]

				C. M. Roller, G. Zhang, R. G. Troedson, C. L. Leach, P. N. Le Souef, and S. G. Devadason Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children Eur. Respir. J., February 1, 2007; 29(2): 299 - 306. [Abstract] [Full Text] [PDF]

				H. Derendorf, R. Nave, A. Drollmann, F. Cerasoli, and W. Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur. Respir. J., November 1, 2006; 28(5): 1042 - 1050. [Abstract] [Full Text] [PDF]

				C. Leach, P. LeSouef, G. P. Chrousos, L. Ghaly, D. Iezzoni, A. Shedden, and A. G. Harris Mometasone and Beclomethasone Comparison Article Observations Chest, May 1, 2006; 129(5): 1389 - 1391. [Full Text] [PDF]

				S. Wenzel Severe Asthma in Adults Am. J. Respir. Crit. Care Med., July 15, 2005; 172(2): 149 - 160. [Abstract] [Full Text] [PDF]

				R. Petersen, L. Agertoft, and S. Pedersen Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma Eur. Respir. J., December 1, 2004; 24(6): 932 - 937. [Abstract] [Full Text] [PDF]

				M. Dolovich and R. Labiris Imaging Drug Delivery and Drug Responses in the Lung Proceedings of the ATS, December 1, 2004; 1(4): 329 - 337. [Abstract] [Full Text] [PDF]

				J. Winkler, G. Hochhaus, and H. Derendorf How the Lung Handles Drugs: Pharmacokinetics and Pharmacodynamics of Inhaled Corticosteroids Proceedings of the ATS, December 1, 2004; 1(4): 356 - 363. [Abstract] [Full Text] [PDF]

				P. D. Levin, D. Levin, and A. Avidan Medical aerosol propellant interference with infrared anaesthetic gas monitors{dagger} Br. J. Anaesth., June 1, 2004; 92(6): 865 - 869. [Abstract] [Full Text] [PDF]

				O. S. Usmani, M. F. Biddiscombe, S. R. Underwood, and P. J. Barnes Characterization of the Generation of Radiolabeled Monodisperse Albuterol Particles Using the Spinning-Top Aerosol Generator J. Nucl. Med., January 1, 2004; 45(1): 69 - 73. [Abstract] [Full Text] [PDF]

				S. Rohatagi, S. Appajosyula, H. Derendorf, S. Szefler, R. Nave, K. Zech, and D. Banerji Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/Pharmacodynamic Perspective J. Clin. Pharmacol., January 1, 2004; 44(1): 37 - 47. [Abstract] [Full Text] [PDF]

				L. Agertoft and S. Pedersen Lung Deposition and Systemic Availability of Fluticasone Diskus and Budesonide Turbuhaler in Children Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 779 - 782. [Abstract] [Full Text] [PDF]

				S.G. Devadason, T. Huang, S. Walker, R. Troedson, and P.N. Le Souef Distribution of technetium-99m-labelled QVARTM delivered using an AutohalerTM device in children Eur. Respir. J., June 1, 2003; 21(6): 1007 - 1011. [Abstract] [Full Text] [PDF]

				H. M. Janssens, J. C. de Jongste, W. C. J. Hop, and H. A. W. M. Tiddens Extra-Fine Particles Improve Lung Delivery of Inhaled Steroids in Infants: A Study in an Upper Airway Model Chest, June 1, 2003; 123(6): 2083 - 2088. [Abstract] [Full Text] [PDF]

				S. Verbanck, D. Schuermans, M. Paiva, and W. Vincken Nonreversible conductive airway ventilation heterogeneity in mild asthma J Appl Physiol, April 1, 2003; 94(4): 1380 - 1386. [Abstract] [Full Text] [PDF]

				M. K. Tulic and Q. Hamid Contribution of the Distal Lung to the Pathologic and Physiologic Changes in Asthma: Potential Therapeutic Target Roger S. Mitchell Lecture Chest, March 1, 2003; 123 (2009): 348S - 355S. [Abstract] [Full Text] [PDF]

				S. Wenzel Severe/Fatal Asthma Chest, March 1, 2003; 123 (2009): 405S - 410S. [Abstract] [Full Text] [PDF]

				A. Nayak, R. Lanier, S. Weinstein, P. Stampone, and M. Welch Efficacy and Safety of Beclomethasone Dipropionate Extrafine Aerosol in Childhood Asthma: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Chest, December 1, 2002; 122(6): 1956 - 1965. [Abstract] [Full Text] [PDF]

				C. L. Leach, P. J. Davidson, B. E. Hasselquist, and R. J. Boudreau Lung Deposition of Hydrofluoroalkane-134a Beclomethasone Is Greater Than That of Chlorofluorocarbon Fluticasone and Chlorofluorocarbon Beclomethasone* : A Cross-over Study in Healthy Volunteers Chest, August 1, 2002; 122(2): 510 - 516. [Abstract] [Full Text] [PDF]

				T. P. Brock and D. M. Williams Clinical Considerations in the Use of Inhalation Delivery Devices Journal of Pharmacy Practice, August 1, 2001; 14(4): 277 - 295. [Abstract] [PDF]

				K.F. Rabe and D.T. Schmidt Pharmacological treatment of asthma today Eur. Respir. J., July 2, 2001; 18(34_suppl): 34S - 40s. [Abstract] [Full Text] [PDF]